Jazz Pharmaceuticals plc (JAZZ)

業務介紹

Jazz Pharmaceuticals plc是一家生物製藥公司，致力於在美國、歐洲和國際市場上為各種未滿足的醫療需求開發和商業化藥物產品。該公司擁有一系列產品和產品候選藥，主要集中在神經科學領域，包括睡眠醫學和運動障礙；以及腫瘤學領域，包括血液學和實體腫瘤。其主要上市產品包括Xyrem，一種口服溶液，用於治療過度白天嗜睡症（EDS）和癱瘓發作的嗜睡症患者，適用於七歲及以上的患者；Sunosi用於治療嗜睡症患者和阻塞性睡眠呼吸暫停症患者的EDS；Erwinaze用於治療急性淋巴細胞性白血病；Defitelio用於治療成人和兒童肝靜脈閉塞性疾病患者；Vyxeos脂質體注射劑，用於治療新診斷的治療相關急性骨髓性白血病的成人患者；以及Zepzelca用於治療轉移性小細胞肺癌的成人患者。該公司還提供Xywav，一種氧酸鹽產品候選藥，用於治療嗜睡症和癱瘓發作的嗜睡症和特發性過度嗜睡症；JZP-324，一種低鈉氧酸鹽配方，有潛力為嗜睡症患者提供具有臨床意義的選擇；JZP385，一種T型鈣離子通道調節劑，用於治療本發性顫抖症；JZP458，一種重組Erwinia門冬氨酸酶，用於作為多藥物化療方案的組成部分，治療兒童和成人患者；以及JZP150用於治療創傷後壓力症候群。該公司與ImmunoGen, Inc.、Codiak BioSciences, Inc.、Pfenex, Inc.、XL-protein GmbH和Redx Pharma plc簽訂了授權和合作協議。Jazz Pharmaceuticals plc成立於2003年，總部位於愛爾蘭都柏林。

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

公司網址

https://www.jazzpharma.com